pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,540 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT785Endpoints590BioPharma Dive228onclive165BioSpace63Fierce Biotech63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • Nonprofit buys experimental cancer drug to maintain patient access
    In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug.
    STAT · 1mo ago↗ source
  • Study highlights influence of socioeconomic status on children’s brain development
    A new study found that the leading environmental factor influencing brain structure and function is the socioeconomic status of a child's family.
    STAT · 1mo ago↗ source
  • The seeming inevitability of rising healthcare costs
    We’re getting our first signs of where healthcare costs are heading next year. According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges
    Endpoints · 1mo ago
← prev
page 25 of 62
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
↗ source
  • STAT+: Abridge inks deals with Nvidia and Lilly
    Abridge announced new deals with Eli Lilly and Nvidia as it aims to gain an edge in a competitive market.
    STAT · 1mo ago↗ source
  • Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says
    DHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendr…
    Endpoints · 1mo ago↗ source
  • Summit withdraws $500M offering, citing 'market conditions'
    The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars. Summit Therapeutics ditched plans for a $500 milli…
    Endpoints · 1mo ago↗ source
  • STAT+: A suspicious denial pattern in Medicare Advantage
    Major Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.
    STAT · 1mo ago↗ source
  • Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
    Plus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic revie…
    Endpoints · 1mo ago↗ source
  • Camurus’ second CRL for acromegaly drug; Teva details workforce cuts
    Plus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer.…
    Endpoints · 1mo ago↗ source
  • STAT+: Novartis doubles down on molecular glue strategy
    Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Biopharma pay report: Top-paid CSOs, CMOs of 2025
    Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News…
    Endpoints · 1mo ago↗ source
  • Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
    Parabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
    More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
    STAT · 1mo ago↗ source
  • STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
    A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, new data show.
    STAT · 1mo ago↗ source
  • STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
    Proving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.
    STAT · 1mo ago↗ source
  • HHS responds coolly to paper on alcohol risk
    Soda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
    Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib indu…
    Endpoints · 1mo ago↗ source
  • Neion Bio raises $23M Series A to make proteins from chicken eggs
    Neion Bio has secured an oversubscribed $23 million Series A to further develop its technology that uses chicken eggs to make active pharmaceutical ingredients for biologic drugs. The funding rou…
    Endpoints · 1mo ago↗ source
  • Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
    In 2025, Elizabeth Selvin and her colleagues published in Nature Medicine for free. In 2026, it cost them $12,850, she writes.
    STAT · 1mo ago↗ source
  • Opinion: How long Covid’s scientific stalemate made it politically erasable
    Long Covid hasn’t disappeared. It’s just gone underground, writes Steven Phillips.
    STAT · 1mo ago↗ source
  • STAT+: Scientists see promise in NIH proposal to cap number of grants they receive
    Without easy access to leaders within a field or top-of-the-line lab equipment, principal investigators outside top universities often struggle to compete for grants from the NIH.
    STAT · 1mo ago↗ source
  • STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find
    Federal investigation finds Medicare Advantage insurers block rehab care for older adults, only to reverse denials on appeal.
    STAT · 1mo ago↗ source
  • Exclusive: Genentech closes infectious disease unit in wave of research layoffs
    Roche's Genentech underwent another round of layoffs this week in its early research and development group, Endpoints News has learned, which included shuttering two research units and the departur…
    Endpoints · 1mo ago↗ source
  • Diabetes association leader apologizes for expulsion of members, pledges to rebuild trust
    The American Diabetes Association CEO apologizes to five members kicked out of annual convention for distributing protest literature, launches review of what went awry.
    STAT · 1mo ago↗ source
  • Rare disease biotech Beren adds $300M from new financings
    Anxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug. The biotech announced Wednesday that it raised $135 ...
    Endpoints · 1mo ago↗ source